GlassScriptPhysician profile
Terra R Curtis
NPI 1215434550
$2,402.75
in general payments reported to CMS, 2019-2025
26 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $212 · 2022: $181 · 2023: $325 · 2024: $563 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,971 · Education: $38.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,970.65 |
| Education | $38.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $312.80 | 2021-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $270.68 | 2021-2025 | |
| Amgen INC. | $234.09 | 2024-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $227.57 | 2023-2025 | Jynarque |
| Novo Nordisk INC | $208.84 | 2025 | Ozempic, Rybelsus, Tresiba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.66 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $168.85 | 2025 | Tarpeyo |
| Alnylam Pharmaceuticals INC. | $144.17 | 2023-2025 | Oxlumo, Givlaari |
| Baxter Healthcare | $117.23 | 2023 | Renal - Pd |
| Mallinckrodt Hospital Products INC. | $66.66 | 2024-2025 | Acthar, Terlivaz |
| Novartis Pharmaceuticals Corporation | $65.19 | 2025 | |
| Abbvie INC. | $63.95 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $52.14 | 2025 | Ultomiris, Strensiq |
| Vantive US Healthcare LLC | $39.43 | 2025 | Renal - Pd |
| Dexcom, INC. | $29.33 | 2024 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $26.17 | 2025 | Yorvipath |
| Vifor Pharma, INC. | $25.49 | 2025 | Veltassa |
| Recor Medical INC | $23.29 | 2025 | Paradise Ultrasound Renal Denervation System |
| Xeris Pharmaceuticals, INC. | $22.83 | 2024 | Gvoke Hypopen |
| Lilly USA, LLC | $22.27 | 2025 | Jardiance |
| Ardelyx, INC. | $21.02 | 2024 | Ibsrela |
| Corcept Therapeutics | $19.94 | 2025 | Korlym |
| Ultragenyx Pharmaceutical INC. | $19.08 | 2024 | Crysvita |
| Madrigal Pharmaceuticals | $18.27 | 2025 | Rezdiffra |
| Cycle Pharmaceuticals INC | $17.22 | 2025 | Venxxiva |
| Apellis Pharmaceuticals, INC. | $13.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terra Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.